Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EBT: 2009-2024

Historic EBT for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$573.9 million.

  • Cytokinetics' EBT fell 18.95% to -$178.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$602.1 million, marking a year-over-year decrease of 7.41%. This contributed to the annual value of -$573.9 million for FY2024, which is 9.43% down from last year.
  • Per Cytokinetics' latest filing, its EBT stood at -$573.9 million for FY2024, which was down 9.43% from -$524.5 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' EBT registered a high of -$109.9 million during FY2020, and its lowest value of -$573.9 million during FY2024.
  • Over the past 3 years, Cytokinetics' median EBT value was -$524.5 million (recorded in 2023), while the average stood at -$480.7 million.
  • Data for Cytokinetics' EBT shows a maximum YoY slumped of 84.48% (in 2021) over the last 5 years.
  • Cytokinetics' EBT (Yearly) stood at -$109.9 million in 2020, then tumbled by 84.48% to -$202.8 million in 2021, then tumbled by 69.48% to -$343.6 million in 2022, then tumbled by 52.64% to -$524.5 million in 2023, then dropped by 9.43% to -$573.9 million in 2024.